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Abstract
Murine leukemia virus (MLV)-based retroviral vector is widely used for gene transfer. Efficient packaging of the genomic RNA
is critical for production of high-titer virus. Here, we report that expression of the insulin-like growth factor II mRNA binding
protein 1 (IMP1) enhanced the production of infectious MLV vector. Overexpression of IMP1 increased the stability of viral
genomic RNA in virus producer cells and packaging of the RNA into progeny virus in a dose-dependent manner.
Downregulation of IMP1 in virus producer cells resulted in reduced production of the retroviral vector. These results indicate
that IMP1 plays a role in regulating the packaging of MLV genomic RNA and can be used for improving production of
retroviral vectors.
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Introduction
Murine leukemia virus (MLV)-based retroviral vector is widely
used for gene transfer in clinical applications and basic research.
The most commonly encountered problem is that the virus titer is
too low. Retroviral vectors produced by DNA transfection of
producing cells usually contain a large amount of non-infectious
virus. The ratio of infectious virions to the total MLV particles
could be as low as 1/100 [1]. The large amount of non-functional
virion particles not only makes it cumbersome and costly to
increase the titers of retroviral vectors for gene therapy but also
produces a noise for virology research. Inactivation of progeny
viruses can be attributed to abrogation or impairment of viral
structural proteins, enzymes or viral genomic RNAs [2–6]. Great
efforts have been made to increase the proportion of functional
retroviral vectors. The strategies include optimizing the recipe of
culture medium [7,8], cultivation temperature [9] and feeding
schedule of virus producer cells [10–13], improving the packaging
cell lines [14,15], modifying the stoichiometric proportion of viral
proteins and viral genomic RNAs [16,17], and removing the non-
infectious particles[18].
In vitro experiments suggested that host cells control the
production of genomic RNA-deficient virus. The synthesis of such
deficient virus was greatly different in different host cells [2],
suggesting that some cellular factors may be involved in
determining the viral genomic RNA packaging efficiency. It also
suggests that it is possible to improve viral genomic RNA packaging
and thereby infectivity of retroviral vectors by manipulating the
expression of some cellular factors in the producer cells.
For the wild type replication-competent MLV virus, the
genome-length viral RNAs of MLV are believed to be separated
into two non-equilibrating pools in virus producer cells, with one
serving as mRNA for translation of Gag and Gag/Pol polyproteins
and the other as genomic RNA for packaging [19–25]. Studies
addressing the preference of homodimerization of MLV viral
genomic RNAs suggest that the fates of the unspliced viral RNAs
as mRNAs or genomic RNAs are determined immediately after
transcription and that these two populations still can exchange
before genomic RNA dimer maturation [25]. Since Gag alone is
able to form virus like particles, some of the progeny viruses are
possibly empty when the levels of packagable genomic RNAs in
the virus producer cells are low. For MLV vector production, the
viral proteins are usually expressed separately and the viral
genomic RNA is designed only for packaging. Thus, it is possible
to increase the abundance of the genomic RNA in the packaging
pool without affecting the expression of viral proteins and thus
increase the production of infectious retroviral vectors.
Insulin-like growth factor II mRNA binding protein 1 (IMP1) is
a member of the VICKZ family [26], which are highly conserved
RNA-binding proteins involved in posttranscriptional regulation
including RNA trafficking [27], stabilization [28,29] and transla-
tion regulation [30,31]. For example, IMP1, also known as the
coding region determinant-binding protein (CRD-BP), protects c-
myc mRNA from endonuclease cleavage and increases its stability
[28,29]. IMP1 has also been implicated in the regulation of the
translation of certain mRNAs. IMP1 bound specifically to 59
untranlated region of leader 3 mRNA of Insulin-like Growth
Factor II (IGF II), but not leader 4 mRNA, and repressed its
translation [30,31].
Based on the abilities of IMP1 to inhibit the translation and to
increase the stability of some RNAs, we investigated the role of
IMP1 in regulating the production of infectious MLV vectors. Our
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15881results demonstrated that overexpression of IMP1 increased the
viral genomic RNA levels both in virus producer cells and virions
and thereby the production of functional MLV vector.
Results
Overexpression of IMP1 increased the production of MLV
vector in a dose-dependent manner
To test whether expression of IMP1 affected the production of
MLV-luc, a retroviral vector carrying the firefly luciferase reporter
[32,33], IMP1 was overexpressed in MLV-luc producing cells.
The plasmid expressing IMP1 was transiently transfected into
293T cells together with MLV-luc producing constructs. A
plasmid expressing reneilla luciferase was also included to serve
as a control for transfection efficiency and sample handling. The
viruses were used to infect 293 cells, and the luciferase activities in
these cells were measured. The firefly luciferase activity normal-
ized by the reneilla lucirferase activity was used as an indicator for
virus production. IMP3, an IMP family member with high
similarity to IMP1, was used for comparison. In the producer cells
transfected with IMP1, the expression of viral Gag protein was
little affected (Fig. 1A), and the normalized firefly luciferase activity
was modestly lower compared with that in the cells transfected
with empty vector or IMP3 (Fig. 1B). In contrast, the normalized
firefly luciferase activity in the recipient cells infected with MLV-
luc produced in the presence of IMP1 was much higher than that
Figure 1. Overexpression of IMP1 in producer cells increased the production of infectious MLV vector in a dose-dependent manner.
The MLV vector producing constructs pCMV-VSVG, pHIT60 and pMA-Luc in a total of 3.6 mg at the ratio of 1.3:1.3:1, and 0.01 mg of pRL-TK, a plasmid
expressing renilla luciferase, were cotransfected into 293T cells in 10 cm dishes together with 0.4 mg of empty vector, pcDNA4-IMP1 or pcDNA4-IMP3
(A–C), or with the indicated amounts of IMP1 (D–F). At 48 h posttransfection, the virus was harvested to infect 293 cells and the luciferase activities in
the producer cells were measured. At 48 h postinfection, the luciferase activity was measured in the recipient cells. (A) (D) The indicated proteins in
the producer cells or virions were detected by Western blotting. (B) (E) Firefly luciferase activity normalized by reneilla luciferase activity in the
producer cells. (C) (F) Firefly luciferase activity in the recipient cells normalized by reneilla luciferase activity in the producer cells. The data are means
6 SD of three independent measurements. *denotes p,0.05, **denotes p,0.01.
doi:10.1371/journal.pone.0015881.g001
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PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15881Figure 2. IMP1 increased viral genomic RNA packaging into virions. The MLV-luc producing constructs pCMV-VSVG, pHIT60 and pMA-Luc
were cotransfected into 293T cells with empty vector, pcDNA4-IMP1 or pcDNA4-IMP3. At 48 h posttransfection, the virus was collected, purified by
25%/45% step gradient centrifugation and then concentrated by centrifugation through 25% sucrose cushion. Equal amounts of virions were used for
further analyses, as judged by the levels of CA measured by Western blotting. The viral genomic RNA was isolated by Trizol extraction. To help sample
handling, 10 mg of the total RNA of 293cells was addedto eachvirussamplebeforeperforming RNA-extraction. Thesamples were treated with DNaseI
to remove possible plasmid DNA contamination. The viral genomic RNA levels were measured by RT-PCR or quantitative RT-PCR (qPCR). The purified
virus was also used to infect 293 cells to measure the infectivity. The Hirt DNA was extracted from the infected cells and the levels of viral DNA were
measured by PCR. (A) The purified virions were resuspended. An aliquot was lysed by boiling in the sample buffer and subjected to Western blotting
using anti-CA antibody (upper). Another aliquot was assayed for the RT activity by the homopolymer assay (lower). (B) The viral genomic RNA and the
extrinsic total RNA of 293 cells were extracted. An aliquot of the RNA was subjected to electrophoresis followed by ethedium bromide staining. (C) (D)
The RNA was reverse transcribed using oligo(dT)18 as the primer. The levels of the cDNA were analyzed by PCR (C) or qPCR (D). GAPDH from the added
cellular RNA was used as an internal control. The qPCR data are means 6 SD from three independent measurements. *denotes p,0.05. (E) The virus
samples at the indicated dilution were used to infect 293 cells. At 12 h postinfection, Hirt DNA was extracted and the levels of the indicated viral DNAs
were measured by PCR. HI: heat-inactivated virus. (F) An aliquot of the virus was used to infect 293 cells. At 48 h postinfection, the cells were lysed and
the luciferase activity was measured. The data are means 6 SD from three independent measurements. *denotes p,0.05.
doi:10.1371/journal.pone.0015881.g002
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IMP1 (mIMP1) and human IMP1 (hIMP1) affected MLV-luc
production similarly (data not shown) and mIMP1 was used in
later experiments.
To test whether IMP1 enhanced the production of infectious
MLV-luc in a dose-dependent manner, different amounts of the
IMP1-expressing plasmid was transfected with the MLV-luc
producing constructs. Consistent with the above results, the
expression levels of Gag protein in the producer cells were little
changed (Fig. 1D), and the luciferase activity in the producer cells
was reduced by about 50% (Fig. 1E) at high dosages. In contrast,
IMP1 overexpression increased the luciferase activity in the
recipient cells in an IMP1 dose-dependent manner (Fig. 1F). These
results established that overexpression of IMP1 enhanced the
production of infectious MLV-luc pseudovirus.
IMP1 increased viral genomic RNA incorporation
To test whether IMP1 facilitated the incorporation of viral
genomic RNA into the virions, the viral genomic RNA levels in
the virion particles were measured. MLV-luc pseudovirus
produced in the presence of empty vector, IMP1 or IMP3 were
purified and concentrated. The same amounts of virion particles
were used, as indicated by the amount of capsid (CA) protein in
the virions (Fig. 2A, upper panel). The reverse transcriptase (RT)
activity in the virions was first measured by the homopolymer RT
assay and no difference was observed (Fig. 2A, lower panel),
indicating that IMP1 overexpression did not increase the
incorporation of RT into the virions. The viral genomic RNA
was extracted from the virions. To help sample handling, total
RNA of naı ¨ve 293 cells was added to each virus sample before
performing RNA-extraction, which also served as an indicator for
the quality of the RNA sample (Fig. 2B). The viral genomic RNA
levels were first analyzed by reverse transcription followed by
PCR. Indeed, the RNA level in the virions produced in the IMP1-
expressing cells was significantly higher than that produced in the
control cells (Fig. 2C). When measured by quantitative PCR, the
RNA level in the virions produced in the IMP1-expressing cells
was about 3.5-fold of that in the virions produced in the control
cells (Fig. 2D). To confirm that the viral genomic RNA in the
virions produced in the IMP1-expressing cells was functional, 293
cells were infected with the virus and the viral DNAs in the
recipient cells were analyzed. As expected, higher level of viral
DNA was detected in the cells infected with the virus produced in
the IMP1-expressing cells (Fig. 2E). Consistent with the previous
results (Fig. 1C), when the same samples of virus were used to
infect 293 cells, the luciferase activity in the recipient cells infected
with virus produced in IMP1-expressing cells was about 5-fold of
that in the cells infected with virus produced in the control cells
(Fig. 2F).
IMP1 bound to and stabilized MLV-luc RNA in the virus
producer cells
The increased incorporation of MLV-luc RNA into the virion
particles could be accounted for by increased abundance of the
RNA in the producer cells or more efficient encapsidation of the
RNA into the virions, or both. To test these possibilities, we first
analyzed whether IMP1 bound to the viral genomic RNA in the
producer cells. IMP1 was co-expressed with MLV-luc (Fig. 3A) in
293T cells. IMP1 was immunoprecipitated (Fig. 3B, upper panel)
and the associated viral genomic RNA was detected by RT-PCR
(Fig. 3B lower panel). Indeed, immunoprecipitation of IMP1
precipitated MLV-luc RNA (Fig. 3B). These results demonstrated
that IMP1 bound MLV-luc RNA.
To test whether expression of IMP1 increased the abundance of
the viral genomic RNA in the producer cells, the viral genomic
RNA levels in the producer cells were analyzed by Northern
blotting. In the IMP1-expressing cells, the viral genomic RNA
level was significantly higher compared with that in the control
cells (Fig. 4A). When increasing amounts of IMP1-expressing
plasmid were transfected, the viral genomic RNA level increased
in an IMP1 dose-dependent manner (Fig. 4B). These results
suggested that IMP1 might increase the stability of the viral
genomic RNA in the producer cells. To test this possibility,
actinomycin D was added to the cells to stop transcription and the
viral genomic RNA levels were analyzed at various time points.
Indeed, the half-life of the viral genomic RNA in IMP1-expressing
cells was significantly prolonged compared with that in the control
Figure 3. IMP1 bound to MLV-luc RNA. pMA-luc was transfected
together with pcDNA4-IMP1 or empty vector into 293T cells in 6 cm
dishes. (A) At 48 h posttransfection, the cells were harvested. The
expression of IMP1 was examined by Western blotting (upper) and the
expression of MLV-luc RNA was detected by Northern blotting (lower).
(B) The cell lysates were immunoprecipitated with anti-myc antibody
and Protein G beads. An aliquot of the beads was used to examine the
immonuprecipitation of IMP1 by Western blotting (upper). The RNA
bound to the beads was extracted and detected by RT-PCR (lower). Ab:
anti-myc antibody; RT: reverse transcriptase.
doi:10.1371/journal.pone.0015881.g003
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PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15881Figure 4. IMP1 stabilized the viral genomic RNA in the producer cells. (A) The MLV-luc vector producing constructs were cotransfected into
293T cells with empty vector, pcDNA4-IMP1 or pcDNA4-IMP3. At 48 h posttransfection, the total RNA was extracted and subjected to Northern
blotting analysis (upper). The relative levels of the viral genomic RNA were measured using Phosphoimager and normalized by the GAPDH mRNA
levels (lower). The data are means 6 SD from three independent measurements. *denotes p,0.05. (B) The MLV vector producing constructs were
cotransfected into 293T cells in 10 cm dishes together with the indicated amounts of pcDNA4-IMP1. At 48 h posttransfection, total RNA was
extracted and subjected to Northern blotting analysis (upper). The relative levels of the viral RNA were measured using Phosphoimager and
normalized by the GAPDH mRNA levels (lower). (C) pMA-Luc was cotransfected with empty vector or pcDNA4-IMP1 into 293T cells. At 24 h
posttransfection, the cells were equally divided into 7 dishes and 12 h later actinomycin D was added to the media at a final concentration of 5 mg/
ml. At the indicated time points, the cells were lysed and the RNA was extracted and subjected to Northern blotting analysis (upper). The relative
levels of the viral RNA were measured using Phosphoimager and normalized by the GAPDH mRNA levels (lower). The data are means 6 SD from two
independent measurements.
doi:10.1371/journal.pone.0015881.g004
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MLV-luc RNA in the producer cells.
IMP1 was incorporated into virion particles
We then further analyzed whether IMP1 was incorporated into
virion particles. APOBEC3G, which has been shown to be
incorporated into virions [34], was used as a positive control. The
virions produced from the cells overexpressing IMP1 were
harvested, purified by sucrose step gradient centrifugation and
analyzed by western blotting. The level of IMP1 was comparable
to that of APOBEC3G in the virion particles (Fig. 5A), suggesting
that IMP1 was incorporated into the virions. To further
substantiate this notion, the virions were subjected to sucrose
gradient ultracentrifugation and the distribution patterns of IMP1
and the CA protein were analyzed. As expected, IMP1 co-
migrated with CA (Fig. 5B), further indicating that IMP1 was
incorporated into the virions.
Depletion of IMP1 reduced production of infectious MLV-
luc vector
To explore whether endogenous IMP1 regulated the production
of retroviral vectors, the expression level of IMP1 was downreg-
ulated by RNA interference in the producer cells and the
production of MLV-luc vector was assayed. The plasmids
expressing shRNAs directed against hIMP1 were first confirmed
for their ability to downregulate the expression of hIMP1 in 293
cells (Fig. 6A). MLV-luc producing constructs were cotransfected
with the plasmid expressing IMP1 shRNA. The virus was used to
infect 293 cells. Downregulation of the endogenous hIMP1 did not
affect the expression of Gag in the producer cells (Fig. 6B, upper
panel), the protein level of CA in the virions (Fig. 6B, lower panel),
or the luciferase activity in the producer cells (Fig. 6C). However,
the luciferase activity in the recipient cells was significantly reduced
(Fig. 6D). Cotransfection of an IMP1 rescue plasmid removed the
inhibitory effect of IMP1 shRNA (Fig. 6D) Similar experiments
were also performed in NIH3T3 cells and similar results were
observed (Fig. 6E-H). These results indicated that endogenous
IMP1 also regulated the production of retroviral vectors.
IMP1 had little effect on the production of wild-type MLV
To examine whether IMP1 exerts the same effect on the
production of wild-type MLV, the virus was produced in the
presence of IMP1. Consistent with the above result that IMP1
inhibited the expression of luciferase from the viral genomic RNA
(Fig. 1B and E), the protein levels of CA and RT were both
reduced in the presence of IMP1 (Fig. 7A). In contrast, the
genomic RNA level in the virions, as measured by the endogenous
RT assay, was increased in the presence of IMP1 (Fig. 7B). The
effect of IMP1 on the production of wild-type MLV was further
evaluated by measuring the propagation of the virus produced in
the absence or presence of IMP1. To demonstrate that this assay
was sensitive enough to detect subtle difference in the amount of
the input virus, different amounts of virus was used to infect Rat2
cells. The propagation of the virus was monitored by measuring
the RT activity in the supernatants. As expected, IMP1 had little
effect on the production of wild-type MLV (Fig. 7C).
Discussion
Efficient packaging of virial genomic RNA is critical for the
production of high-titer retroviral vectors. In this report, we
demonstrated that overexpression of IMP1 in the producer cells
facilitated the packaging of viral genomic RNA and thereby
improved the production of infectious MLV-luc vector in an IMP1
expression level-dependent manner (Fig. 1, 2). Further analyses
revealed that IMP1 increased the stability of the viral genomic
RNA in the producer cells (Fig. 4). It is believed that the newly
synthesized unspliced mRNA of MLV are sorted into two non-
equilibrating pools, with one serving as the mRNA for translation
and the other as the genomic RNA for packaging [19–25,35]. The
luciferase activity expressed form the viral genomic RNA was
modestly but consistently inhibited in the producer cells (Fig. 1B).
This result suggests that in addition to stabilizing viral genomic
RNA, IMP1 may also modulate the distribution of the viral
genomic RNA in the two pools. This notion is consistent with the
observations that expression of IMP1 increased the abundance of
the viral genomic RNA in the producer cells by about 2-fold
(Fig. 4A) but increased the RNA level in the virions by about 3.5-
fold (Fig. 2D). Whether IMP1 is involved in RNA encapsidation
awaits further investigation. Furthermore, since IMP1 bound to
the viral genomic RNA (Fig. 3) and was incorporated into the
virion particles (Fig. 5), it may also help reverse transcription. This
would be consistent with the observations that IMP1 increased the
RNA level in the virions by about 3.5-fold (Fig. 2D) but increased
the titer of the virus by more than 5-fold (Fig. 2F). Further
investigation is needed to explore whether and how IMP1 is
involved in reverse transcription.
The stimulatory effect of IMP1 on the production of infectious
virion particles was specific only for retroviral vectors. In the
retroviral vector producing cells, the viral proteins are expressed
from constructs separate from that expressing the viral genomic
RNA. Therefore, IMP1 increased the abundance of the viral
genomic RNA in the pool for packaging without affecting the
Figure 5. IMP1 was incorporated into the virion particles.
Plasmids expressing myc-tagged IMP1 or APOBEC3G (A3G) was
cotransfected with the MLV-luc vector producing constructs into 293T
cells in 6 cm dishes. At 48 h post transfection, the viruses were
collected. (A) The virions were purified first by centrifuging through
25%/45% sucrose step gradient and then centrifuged through 25%
sucrose cushion. The indicated proteins in the producer cells and virions
were analyzed by Western blotting. (B) The purified viruses were
applied to 10–60% linear sucrose gradient centrifugation at 25,000 rpm
for 16 h. Fractions were collected, and proteins were precipitated by
Trichloroacetic acid (TCA)/actone and analyzed by Western blotting.
doi:10.1371/journal.pone.0015881.g005
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unspliced viral RNA serves as both genomic RNA for packaging
and mRNA for translation. IMP1 inhibited the expression of the
viral proteins while increased the incorporation of viral genomic
RNA into the virions (Fig. 7A and B). As a consequence,
overexpression of IMP1 had little effect on the production of wild-
type MLV (Fig. 7C).
In contrast to the stimulatory effect of IMP1 on MLV vectors, it
has been reported that IMP1 bound to HIV-1 RNA but inhibited
viral genomic RNA packaging [36]. It seems that how IMP1 binds
to the viral genomic RNA also affects the effect of IMP1 on viral
genomic RNA packaging. Due to the limited number of the targets
of IMP1 so far identified [37–39], the consensus IMP1 binding site
is not clear yet. It is conceivable that sequence variation in the
Figure 6. Downregulation of IMP1 in producer cells reduced the production of infectious MLV vector. (A) The plasmid expressing myc-
tagged hIMP1 was cotransfected into 293 cells in 3.5 cm dishes with the shRNA directed against hIMP1 alone or with the shRNA plus myc-tagged
mIMP1. The expression levels of IMP1-myc were measured by Western blotting using the anti-myc antibodies. 4i and 9i: shRNAs directed against
different sequences of hIMP1; R-20: shRNA 9i plus 20 ng of mIMP1-expressing plasmid; R-40: shRNA 9i plus 40 ng of mIMP1-expressing plasmid. (E)
The plasmid expressing myc-tagged mIMP1 was cotransfected into 293 cells in 3.5 cm dishes with the shRNA directed against mIMP1 alone or with
the shRNA plus myc-tagged hIMP1. The expression levels of IMP1-myc were measured by Western blotting using the anti-myc antibodies. 26i:
shRNAs directed against sequence of mIMP1; R-200: shRNA 26i plus 200 ng of hIMP1-expressing plasmid; R-500: shRNA 26i plus 500 ng of hIMP1-
expressing plasmid. The plasmids expressing the indicated shRNAs were transfected into 293T cells (B–D) or NIH 3T3 cells (F–H). At 24 h
posttransfection, the cells were transfected again with the shRNA-expressing plasmids, together with MLV vector producing constructs and reneilla
luciferase expressing plasmid pRL-TK. At 48 h posttransfection, the virus was harvested to infect 293 cells. At the same time, luciferase activities in the
producer cells were measured. At 48 h postinfection, the luciferase activity in the recipient cells was measured. (B) (F) The indicated proteins in the
producer cells or virions were detected by Western blotting. (C) (G) Firefly luciferase activity normalized by the reneilla luciferase activity in the
producer cells. (D) (H) Firefly luciferase activity in the recipient cells normalized by the reneilla luciferase activity in the producer cells. The data are
means 6 SD of three independent measurements. *denotes p,0.05.
doi:10.1371/journal.pone.0015881.g006
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15881Figure 7. IMP1 had little effect on the production of wild-type MLV. The wild-type MLV producing construct, pNCS, was transfected into
293T cells in 6 cm dishes with the indicated amounts of IMP1-expressing plasmid. (A) At 48 h postinfection, the viral protein levels were measured by
Western blotting and the RT activity in the virions was measured by the homopolymer assay. (B) At 48 h posttransfection, the virus produced in the
absence or presence of 40 ng IMP1 was collected, purified by 25%/45% step gradient centrifugation and then concentrated by centrifugation
through 25% sucrose cushion. Virions containing equal amount of CA, as judged by Western blotting (middle panel), was used to perform the
endogenous RT assay. Viral DNA products were detected by PAGE and autoradiograph (upper panel). (C) The indicated amounts of MLV produced in
the absence or presence of 40 ng IMP1 were used to infect Rat2 cells. The virus propagation was monitored by measuring the RT activity in the
supernatant. Input: the RT activity in the supernatant used to infect Rat2 cells.
doi:10.1371/journal.pone.0015881.g007
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stimulatory effect of IMP1 on the production of these vectors. For
a particular retroviral vector, experimental test may be needed to
evaluate the effect of IMP1 on the production of the vector.
Materials and Methods
Plasmids
MLV producing plasmids pCMV-VSVG, pHIT60 and pMA-
Luc have been previously described [32,33]. Wild type MLV
producing plasmid pNCS has been previously described [40]. The
sequences encoding mIMP1 and mIMP3 were PCR amplified
from a mouse cDNA library and cloned into pcDNA4/TO/myc-
HisB (Invitrogen). pcDNA4/TO/myc-HisB-APOBEC3G (A3G)
was constructed by a cloning the coding sequence of A3G into
pcDNA4/TO/myc-HisB such that A3G is tagged with the myc-
epitope at the C-terminus. The primers are listed below, with the
built-in restriction sites underlined:
IMP1-SP: 59-CCGGAATTCGCCACCATGAACA AGCTT-
TACATCGG-39;
IMP1-AP: 59-AAGGAAAAAAGCGGCCGCCCTTCCTCC-
GAGCCTGGGCCA -39;
IMP3-SP: 59-CCCAAGCTT GCCACCATGAACAAATTG-
TACATCGGGAA-39;
IMP3-AP: 59 -CCGGAATTCGCCTTCCGCCTTGACTGA-
GGTG-39;
To generate the shRNAs directed against IMP1, oligonucleotides
were designed and cloned into pSuper following the manufacturer’s
instruction (OligoEgine). The antisense sequence of the shRNAs
directed against mIMP1 and hIMP1 are listed below:
mIMP1-26i: 59- TTATGAGCCAGGATCTTCAGGG-39.
hIMP1-4i: 59- TCTTGCTCTACCTTCTTCA-39;
hIMP1-9i: 59-TTTCACGATGACCTGGTCG-39.
Cell culture
NIH 3T3 cells (ATCC CRL-1658), Rat2 cells (ATCC CRL-
1764), 293 cells (ATCC CRL- 1573) and 293T cells (ATCC CRL-
11268) were maintained in DMEM supplemented with 1%
antibiotics and 10% fetal bovine serum (Invitrogen).
To produce VSV-G pseudotyped MLV-luc, pCMV-VSV-G,
pHIT60 and pMA-Luc were transfected into 293T cells. The
reneilla expressing plasmid, pRL-TK (Promega), was included to
serve as a controlfor transfection efficiency and sample handling.At
48 h post transfection, the supernatants were collected, centrifuged
at 2,000 rpm for 5 min and filtered through 0.45 mm filters to
remove cell debris. To purify and concentrate the virion particles,
supernatants were first subjected to 25%/45% sucrose step gradient
centrifugation at 25,000 rpm with Hitachi P40ST rotor for 2 h at
4uC and then concentrated by ultracentrifugation with 25% sucrose
cushion for 2 h. The pellets were resuspended in TNE buffer
(50 mM Tris-HCl pH 7.5, 100 mM NaCl and 1 mM EDTA) and
stored at 280uC for future use.
The luciferase activities were measured 48 h after transfection
or infection by the dual luciferase assay system following the
manufacturer’s instruction (Promega).
Antibodies
The mouse monoclonal antibody 9E10 (Santa Cruz Biotech-
nology) was used to detect proteins with the myc epitope and the
mouse monoclonal antibody M2 (Sigma) was used to detect
proteins with the Flag epitope. The N-terminal domain of MLV-
CA with a His-tag was bacterially expressed and used to immunize
rabbits to generate polyclonal antiserum. The antibody was
affinity purified using the recombinant CA protein. The rabbit
polyclonal antiserum against MLV-RT was a generous gift from
Dr. Stephen Goff of Columbia University, New York, USA.
RT assays
The homopolymer RT assay and the endogenous RT assay
have been previously described [41].
Detection of the viral DNAs
The assays for detecting the minus strand strong stop DNA and
nuclear circular DNA have been previously described [42–43].
Measurement of the viral genomic RNA levels
The virions were lysed in Trizol buffer (Invitrogen). To each
sample, 10 mg of total RNA of 293 cells was added to help as well as
to serve as a control for sample handling. The RNA was extracted,
ethanol precipitated and re-suspended. To remove possible DNA
contamination, the RNA was treated with the DNA Free kit
(Ambion) followed by ethanol precipitation. The viral genomic
RNA level was measured by reverse transcription followed by PCR
or realtime-PCR using specific primers for the minus-strand
strong stop (MSS) DNA [42]. GAPDH was used as a control using
primers GAPDH-FP (59-TCACTGCCACCCAGAAGACTGTG-
G-39) and GAPDH-RP (59-GGTCCACCACCCTGTTGCT GT-
AGCC-39). The PCR conditions for the MSS DNA and GAPDH
were 94uC for 30 s, 55uC for 30 s, and 72uC for 30 s for 21 cycles
for MSS and 22 cycles for GAPDH. The same conditions and
primers were used for realtime-PCR analysis.
To analyze the viral genomic RNA levels in the producer cells,
the cells were trypsinized, washed and lysed in the Trizol buffer
(Invitrogene). The total RNA was isolated following the manufac-
turer’s instruction. The RNA levels were measured by Northern
blotting analysis following the procedure described previously [44].
Detection of retroviral RNA bound to IMP1
pMA-luc was cotransfected with pcDNA4-IMP1 or empty
vector into 293T cells. At 48 h posttransfection, cells were washed
extensively with diethyl pyrocarbonate (DEPC)-treated PBS. A
quarter of the cell was lysed in the Trizol buffer (Invitrogene) to
extract total RNA for analyzing the expression of pMA-luc and
GAPDH RNAs. The rest cells were lysed in the lysis buffer
(10 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 0.01%
sodium deoxycholate). An aliquot of the cell lysate was used to
examine IMP1 expression by Western blotting. The rest lysate was
precleared by incubating with mouse anti-HA antibody and
proteins G-sepharose (Pharmaicia) in the presence of RNasin
(40 u/ml) at 4uC for 2 h, followed by brief centrifugation. The
precleared cell lysate was incubated with new protein G-sepharose
beads with or without 3 ml anti-myc antibody at 4uC for 2 h. The
beads were washed with the washing buffer (10 mM Tris, pH 7.4,
150 mM NaCl, 0.01% sodium deoxycholate) for seven times. The
RNA was extracted with the Trizol buffer, treated with DNase I
(Ambion) and analyzed by RT-PCR to detect the viral RNA as
described above.
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